Rare and Orphan Disease Trials

Global Collaboration in Natural History Initiatives for Rare Diseases

Posted on digi By digi

Rare diseases by definition affect small populations, often scattered across countries and continents. While each rare condition may impact only a few individuals per million, collectively they affect over 400 million people worldwide. In this fragmented landscape, conducting comprehensive natural history studies at a national level often yields limited insights. Global collaboration is essential to pool patients, harmonize data, and accelerate understanding of disease progression.
Click to read the full article.

Natural History Studies, Rare and Orphan Disease Trials

Cost Control Strategies for Rare Disease Clinical Trials

Posted on digi By digi

Rare disease clinical trials often require intensive resources, customized procedures, and complex logistics, making them significantly more expensive per patient than conventional trials. According to a Tufts CSDD analysis, rare disease trials can cost between 2x to 5x more per patient, primarily due to specialized site selection, global dispersion of patients, and lengthy follow-up requirements.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

Comprehensive Guide to FDA Orphan Drug Designation for Rare Disease Clinical Trials

Posted on digi By digi

The Orphan Drug Designation (ODD) program, administered by the U.S. Food and Drug Administration (FDA), was established under the Orphan Drug Act of 1983 to incentivize the development of treatments for rare diseases—defined in the U.S. as conditions affecting fewer than 200,000 individuals. This designation grants sponsors access to significant regulatory, financial, and marketing benefits designed to offset the high cost and risk of developing therapies for small patient populations.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

First Pediatric Approval in a Rare Neurodegenerative Disease

Posted on digi By digi

Neurodegenerative diseases in children represent some of the most devastating rare disorders. Conditions such as spinal muscular atrophy (SMA), Batten disease, and certain leukodystrophies often present in infancy or early childhood, leading to progressive neurological decline, loss of motor skills, seizures, and ultimately shortened life expectancy. For decades, therapeutic options were limited, leaving families with supportive care as the only available pathway. The approval of the first therapy specifically for a pediatric rare neurodegenerative disease marked a turning point in how regulators, researchers, and industry approach orphan drug development.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Effective Vendor Oversight in Orphan Drug Development

Posted on digi By digi

Vendor oversight is a core responsibility of sponsors conducting clinical trials—and in rare disease programs, this function becomes even more critical. Given the complexity of orphan drug development, sponsors often engage multiple vendors across regulatory, data management, central labs, logistics, and patient services.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials

How EMA’s PRIME Scheme Accelerates Rare Disease Therapies

Posted on digi By digi

The Priority Medicines (PRIME) scheme was launched by the European Medicines Agency (EMA) in 2016 to enhance support for the development of medicines targeting unmet medical needs. PRIME provides early and proactive regulatory assistance to optimize development plans and accelerate evaluation for therapies that demonstrate potential to significantly benefit patients—particularly in rare and orphan indications where options are limited or non-existent.
Click to read the full article.

Rare and Orphan Disease Trials, Regulatory Frameworks

Orphan Drug Development Success in Metabolic Disorders

Posted on digi By digi

Metabolic disorders represent some of the most complex and challenging conditions in rare disease research. Many are genetic in origin, such as lysosomal storage diseases, mitochondrial disorders, and inborn errors of metabolism. Patients often experience life-threatening complications, significant morbidity, and limited therapeutic options. Because of their rarity and clinical heterogeneity, these conditions are difficult to study in large randomized controlled trials. The orphan drug designation pathway created under U.S. and EU regulations has been transformative, incentivizing companies to pursue drug development in this area.
Click to read the full article.

Case Studies & Breakthroughs, Rare and Orphan Disease Trials

Conducting QA Audits in Rare Disease Clinical Trials

Posted on digi By digi

Quality Assurance (QA) audits are vital in clinical research, serving as a proactive tool to ensure Good Clinical Practice (GCP) compliance, data integrity, and regulatory readiness. In rare disease trials, these audits carry even greater significance due to the small sample sizes, complex protocols, and higher scrutiny from regulatory authorities such as the FDA, EMA, and PMDA.
Click to read the full article.

Operational Challenges, Rare and Orphan Disease Trials